Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Press Releases
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
CommuniquÚs de presse de la sociÚtÚ ASTELLAS PHARMA INC.
10/13Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV (enfo..
AQ
10/12ASTELLAS PHARMA : and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV..
PU
10/12ASTELLAS PHARMA : Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combini..
BU
10/11ASTELLAS PHARMA : World's First Use of Environmentally Friendly Biomass-based Plastic for ..
PU
10/01ASTELLAS PHARMA : Juntendo University and Astellas Establish "Direct Reprogramming Regener..
PU
09/30ASTELLAS PHARMA : Corporate Strategic Plan 2021—dedicated to realization
PU
09/30ASTELLAS PHARMA : announces the publication of New Contents related to its Corporate Strat..
PU
09/29ASTELLAS PHARMA : Recognized Consistently Among Top Companies for Working Parents
AQ
09/28ASTELLAS PHARMA : Japan's MHLW Approves PADCEV (enfortumab vedotin) for Advanced Urothelia..
AQ
09/27ASTELLAS PHARMA : Japan's MHLW Approves PADCEV (enfortumab vedotin) for Advanced Urothelia..
PU
09/27ASTELLAS PHARMA : Japan's MHLW Approves PADCEV« (enfortumab vedotin) for Advanced Urotheli..
BU
09/23ASTELLAS PHARMA : Tohoku University and Astellas Establish Second Phase of Comprehensive I..
PU
09/23ASTELLAS PHARMA INC. : will present 12-week results (S-13) from the pivotal Phase 3 SKYLIG..
AQ
09/22Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic..
AQ
09/22ASTELLAS PHARMA : to Present Fezolinetant 12-Week Findings from Phase 3 SKYLIGHT 2™ ..
PU
09/21ASTELLAS PHARMA : Science-based Exercise at Home with Fit-eNce HomeTM Pilot Sales Begins T..
PU
09/20ASTELLAS PHARMA : ' and Pfizer's XTANDI« (enzalutamide) Reduced Risk of Death by 34% in Me..
PU
09/20ASTELLAS PHARMA : ' and pfizer's xtandi (enzalutamide) reduced risk of death by 34% in men..
AQ
09/09ASTELLAS PHARMA : Updates “Contact for Potential Acquisition of ' R&D Programs&rdquo..
PU
09/02ASTELLAS PHARMA : Nitto, and M. Heart Partnering for ECG testing service
PU
08/31ASTELLAS PHARMA : Announces Personnel Changes
PU
08/30ASTELLAS PHARMA : Launches its Corporate Website's New Modalities~Approach for Cell..
PU
08/20ASTELLAS PHARMA : Receives European Commission Approval for First-in-Class EVRENZOTM (roxa..
PU
08/19ASTELLAS PHARMA : Receives European Commission Approval for First-in-Class EVRENZO™á..
AQ
08/19ASTELLAS PHARMA : Receives EC Approval for First-inClass EVRENZO (roxadustat) for Adult Pa..
PU
08/06ASTELLAS PHARMA : Reforms Research Organization
PU
07/30ASTELLAS PHARMA : and Minovia Therapeutics Announce Strategic Collaboration for Novel Mito..
BU
07/29ASTELLAS PHARMA : Financial Results (Q1/FY2021)
PU
07/29ASTELLAS PHARMA : Presentation Material for Information Meeting (Q1/FY2021)
PU
07/29ASTELLAS PHARMA : Supplementary Documents (Q1/FY2021)
PU
07/12ASTELLAS PHARMA : U.S. FDA Grants Regular Approval and Expands Indication for PADCEV (enfo..
AQ
07/11ASTELLAS PHARMA : U.S. FDA Grants Regular Approval and Expands Indication for PADCEV(enfor..
PU
07/09ASTELLAS PHARMA : U.S. FDA Grants Regular Approval and Expands Indication for PADCEV« (enf..
BU
06/29ASTELLAS PHARMA : Corporate Governance Report
PU
06/28ASTELLAS PHARMA : Receives Positive CHMP Opinion for EVRENZO (roxadustat) for Adult Patien..
PU
06/24PFIZER : First participant dosed in pfizer's pivotal phase 3 talapro-3 combination study o..
AQ
06/17ASTELLAS PHARMA : Notice Regarding Impairment Loss Following the Termination of DNA Vaccin..
PU
06/16ASTELLAS PHARMA : Transfers Five Legacy Products in Europe, Russia, CIS and Asia to Chepla..
PU
06/09ASTELLAS PHARMA : New Research Reflects Astellas' Commitment to Acute Myeloid Leukemia at ..
AQ
06/02ASTELLAS PHARMA : Reviewing capabilities for sustainable growth - Astellas Will Offer an E..
PU
05/20ASTELLAS PHARMA : and Seagen Announce Updated Results from Two Trials of PADCEV (enfortuma..
AQ
05/19ASTELLAS PHARMA : Seagen and Astellas Announce Updated Results from Two Trials of PADCEV« ..
BU
05/18Astellas to Present Data from Expanding Oncology Portfolio During the 2021 ASCO Annual ..
AQ
05/12ASTELLAS PHARMA : Notice Regarding Continuation of the Performance-linked Stock Compensati..
PU
05/06ASTELLAS PHARMA : ' XTANDI (enzalutamide) Approved by European Commission for Men with Met..
PU
05/05ASTELLAS PHARMA : ' XTANDI (enzalutamide) Approved by European Commission for Men with Met..
AQ
04/28ASTELLAS PHARMA INC. : - Notice Regarding Impairment Loss for Investigational Gene Therapy..
AQ
04/28ASTELLAS PHARMA INC. : - Change of Directors
AQ
04/27ASTELLAS PHARMA : Change of Directors
PU
04/26ASTELLAS PHARMA : Notice Regarding Impairment Loss for Investigational Gene Therapy AT132 ..
PU
04/20ASTELLAS PHARMA : and Seagen Announce U.S. FDA Acceptance of Two Supplemental Biologics Li..
AQ
04/20ASTELLAS PHARMA : and Seagen Announce FDA Acceptance of Two Supplemental Biologics License..
PU
04/13ASTELLAS PHARMA : Updates 'Contact for Potential Acquisition of ' R&D Programs' Section on..
AQ
04/04ASTELLAS PHARMA : and TOA EIYO Announce Termination of Distribution Agreement
PU
04/01ASTELLAS PHARMA : Establishes ' Gene Therapies' as its Global Gene Therapy Center of Excel..
AQ
04/01ASTELLAS PHARMA : and TB Alliance Enter into a New Collaborative Research Agreement to Ide..
AQ
04/01ASTELLAS PHARMA : Announces Termination of Co-promotion with Viatris for Lipitor Tablets
PU
03/29ASTELLAS PHARMA : ' XOSPATA Meets Overall Survival Endpoint in COMMODORE Trial
PU
03/29ASTELLAS PHARMA : Garners New Indication and New Product Formulation Approvals from U.S. F..
AQ
03/29ASTELLAS PHARMA INC. : - European Medicines Agency Accepts Marketing Authorization Applica..
AQ
03/29ASTELLAS PHARMA : Receives Positive CHMP Opinion for XTANDI for Patients with Metastatic H..
AQ
03/29ASTELLAS PHARMA : Receives Positive CHMP Opinion for XTANDITM for Patients with Metastatic..
AQ
03/26ASTELLAS PHARMA INC. : - Doshisha University, Wakayama Medical University and Astellas ann..
AQ
03/26ASTELLAS PHARMA : Garners New Indication & New Product Formulation Approvals From U.S. FDA..
PU
03/25ASTELLAS PHARMA : Oncology Announces Grand Prize Winner of Fifth Annual C-3 Prize Challeng..
AQ
03/24ASTELLAS PHARMA : Presentation Material for Astellas Rx+ Day(Media Seminar)
PU
03/19ASTELLAS PHARMA : Efforts against the Spread of the Coronavirus Disease
AQ
03/11ASTELLAS PHARMA : Submits New Drug Application for Enfortumab Vedotin in Japan
PU
03/01ASTELLAS PHARMA : Notice Regarding Continuation of the Performance-linked Stock Compensati..
AQ
02/26ASTELLAS PHARMA : Notice Regarding Continuation of the Performance-linked Stock Compensati..
PU
02/22ASTELLAS PHARMA : Announces Positive Topline Results from Two Phase 3 Pivotal Global Trial..
AQ
02/19ASTELLAS PHARMA : and Seagen Announce Submission of Two Supplemental Biologics License App..
AQ
02/15SEAGEN : and Astellas Announce Phase 3 Trial Results Demonstrating Survival Advantage of P..
AQ
02/15ASTELLAS PHARMA : and Seagen Announce Presentation of Results from PADCEV Pivotal Trial in..
AQ
02/04ASTELLAS PHARMA : XOSPATA Receives Conditional Approval by China's National Medical Produc..
AQ
1  2  3  4  5  6  7  8Next
Upcoming event on ASTELLAS PHARMA INC.
10/29/21